Drug Treatment

2013 LRG Research Team Progress Report

Accomplishments—Recent Progress: 1. Using mouse models, successfully attacked GIST with antibodies, essentially telling immune system to eat the cancer cells.

The Life Raft Group Attends 18th Annual CTOS Meeting in NYC

From October 30th to November 2nd the Life Raft Group staff members attended the annual Connective Tissue Oncology Society (CTOS) Meeting in NYC.

By |2019-09-20T11:36:08-04:00December 6th, 2013|Advocacy, Clinical Trials, Drug Treatment, News, Research|

FDA asks ARIAD to suspend marketing and sales of Iclusig (ponatinib)

The U.S. Food and Drug Administration (FDA) has asked ARIAD Pharmaceuticals, the manufacturer of Iclusig (ponatinib) to suspend marketing and sales of ponatinib because of the risk of life-threatening blood clots and severe narrowing of [...]

By |2019-09-20T11:38:58-04:00November 1st, 2013|Drug Treatment, News|

Stivarga Approved for Canadian GIST Patients

Health Canada has expanded approval for the use of Stivarga to fight Gastrointestinal Stromal Tumours (GIST), according to an article from CNW. Bayer announced that Stivarga will now be available for treatment of adult patients with [...]

By |2019-09-20T11:39:34-04:00October 18th, 2013|Drug Treatment, News, Stivarga|

Stivarga Approved to Treat GIST Patients in Japan

Stivarga has just been approved in Japan for the treatment of GIST. Keep reading for more information.Official Stivarga Press Release:Bayer HealthCare has received approval from the Japanese authorities (MHLW) for the marketing of Regorafenib (Stivarga) [...]

By |2019-09-20T12:04:14-04:00August 21st, 2013|Drug Treatment, News, Stivarga|
Go to Top